(Q34370627)

1 August 2017

title

Antibody therapeutics in cancer. (English)

1 reference

1 August 2017

1 reference

Mark X Sliwkowski

1

1 reference

1 August 2017

Ira Mellman

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 September 2013

1 reference

1 August 2017

1 reference

1 August 2017

volume

341

1 reference

1 August 2017

issue

6151

1 reference

1 August 2017

page(s)

1192-1198

1 reference

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Cetuximab in the treatment of patients with colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

EGFR-targeting monoclonal antibodies in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Mylotarg: antibody-targeted chemotherapy comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Why is it so difficult to use gemtuzumab ozogamicin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

BiTEs: bispecific antibody constructs with unique anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Engineered therapeutic antibodies with improved effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCIENCE.1241145

21 January 2018

Identifiers

DOI

10.1126/SCIENCE.1241145

1 reference

1 August 2017

1 reference